Vimarsana
Biggest News Aggregation in the World

Greig Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Greig Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Greig Communications Today - Breaking & Trending Today

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator - Vimarsana News

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

BOSTON & PRINCETON, N.J.--(BUSINESS WIRE)--May 29, 2024--

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway - Vimarsana News

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30%Unaudited cash, cash equivalents, and marketable securities totaling...

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development - Vimarsana News

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

PC14586 clinical program to be led by Deepika Jalota, Pharm.D. and Marc Fellous, M.D. Michael Carulli promoted to Chief Financial OfficerRobert Ticktin, General Counsel, will expand responsibilities...

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma - Vimarsana News

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV+ lymphoma subtypes, including some of the...

Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer - Vimarsana News

Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

SAN DIEGO, Aug. 07, 2023 -- Viracta Therapeutics, Inc. , a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...